Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

US to offer free COVID tests in September as part of fall campaign

Published 08/23/2024, 12:11 PM
Updated 08/23/2024, 02:31 PM
© Reuters. FILE PHOTO: A woman works inside a mobile coronavirus disease (COVID-19) testing center in the Midtown area of New York City U.S., August 21, 2023.  REUTERS/Shannon Stapleton

By Manas Mishra and Julie Steenhuysen

(Reuters) -The U.S. government will provide free COVID-19 tests by mail starting in late September, as it kicks off a fall campaign urging eligible Americans to get vaccinated against COVID, flu and RSV, health officials said on Friday.

Households can order up to four free tests through COVIDTests.gov, officials from the U.S. Centers for Disease Control and Prevention and the Department of Health and Human Services said at a press briefing.

The popular free testing program has had several rounds since it started in January 2022.

This year, the government campaign is timed to the fall and winter seasons, when temperatures drop and people stay indoors more, Dawn O'Connell, assistant secretary for preparedness and response at the HHS said.

COVID has been on the rise this summer, with hospitalizations jumping from 1.1 per 100,000 people at the beginning of May, to 4.4 at the beginning of August. The number of deaths has also risen during that period.

Health officials said even though previous vaccines and infection provide some immunity, people should get the updated shots, approved on Thursday, and also test.

"The virus continues to change faster than the flu virus," said U.S. CDC Director Mandy Cohen.

"The severity of COVID looks more similar to flu, but if you still put head-to-head... in terms of what is hospitalizing more folks and what is killing more folks, COVID is being (a) more dangerous virus than flu," Cohen said.

She also said COVID was now endemic, but there were tools to protect people.

© Reuters. FILE PHOTO: A woman works inside a mobile coronavirus disease (COVID-19) testing center in the Midtown area of New York City U.S., August 21, 2023.  REUTERS/Shannon Stapleton

The U.S. Food and Drug Administration approved updated mRNA COVID vaccines on Thursday that target a recently circulating variant, in order to better protect the population heading into cold weather.

The updated vaccines include those made by Pfizer (NYSE:PFE), its German partner BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA). The FDA did not clear Novavax (NASDAQ:NVAX)'s traditional protein-based shot and is still reviewing it.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.